At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Fluzone-High Dose Quadrivalent +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Cell Molecular Analysis of Influenza Vaccine Induced T Cell Responses in Adults 65 Years of Age or Older
In Brief
A Phase 4 clinical trial evaluating Fluzone-High Dose Quadrivalent, Fluad, and 1 other intervention for Flu Vaccine. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFlu Vaccine
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartOct 2019
Primary CompletionFeb 2020
TodayJul 2026
First PostedSep 4, 2019
Enrollment StartOct 21, 2019
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.8 years ago
Interventions
Fluzone-High Dose Quadrivalentbiological
Seasonal influenza vaccination with FDA approved vaccines for this age group.
Fluadbiological
Adjuvanted (MF59) inactivated influenza vaccine
Flublockbiological
Recombinant hemagglutinin vaccine